Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjit Akolekar

Showing results (81-90 of 135) with videos related to

Pageof 14
Sort By:
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|February 1, 2021
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeksIoakeim Sapantzoglou, Margarita Gallardo Arozena, Vlad Dragoi, et al.
Clinical Chemistry|February 18, 2011
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitusAna Fatima A Ferreira, Juliana C Rezende, Eirini Vaikousi, et al.
Hypertension (Dallas, Tex. : 1979)|March 11, 2009
First-trimester prediction of hypertensive disorders in pregnancyLeona C Y Poon, Nikos A Kametas, Nerea Maiz, et al.
Prenatal Diagnosis|April 25, 2013
Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complicationsFrancesco D'Antonio, Claudia Rijo, Basky Thilaganathan, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 3, 2025
Preeclampsia screening taking into account ethnicity and socioeconomic status - a comparison of the competing-risks model and risk factor scoringAnastasija Arechvo, Argyro Syngelaki, Ranjit Akolekar, et al.
Hypertension in Pregnancy|March 9, 2010
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancyRanjit Akolekar, Jader De Jesus Cruz, Jose Maria Perez Penco, et al.
American Journal of Obstetrics and Gynecology|May 16, 2016
Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancyKarin B Grossman, Roopen Arya, Alberto B Peixoto, et al.
American Journal of Obstetrics and Gynecology|April 17, 2026
In women with chronic hypertension, does fetal growth restriction increase progression to maternal preeclampsia?Laura A Magee, Christos Chatzakis, Argyro Syngelaki, et al.
Obstetric Medicine|December 12, 2017
Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metforminJyoti Balani, Steve Hyer, Argyro Syngelaki, et al.
American Journal of Obstetrics and Gynecology|February 5, 2020
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspringOlga Panagiotopoulou, Argyro Syngelaki, Georgios Georgiopoulos, et al.
Pageof 14

Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|February 1, 2021
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeksIoakeim Sapantzoglou, Margarita Gallardo Arozena, Vlad Dragoi, et al.
Clinical Chemistry|February 18, 2011
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitusAna Fatima A Ferreira, Juliana C Rezende, Eirini Vaikousi, et al.
Hypertension (Dallas, Tex. : 1979)|March 11, 2009
First-trimester prediction of hypertensive disorders in pregnancyLeona C Y Poon, Nikos A Kametas, Nerea Maiz, et al.
Prenatal Diagnosis|April 25, 2013
Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complicationsFrancesco D'Antonio, Claudia Rijo, Basky Thilaganathan, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 3, 2025
Preeclampsia screening taking into account ethnicity and socioeconomic status - a comparison of the competing-risks model and risk factor scoringAnastasija Arechvo, Argyro Syngelaki, Ranjit Akolekar, et al.
Hypertension in Pregnancy|March 9, 2010
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancyRanjit Akolekar, Jader De Jesus Cruz, Jose Maria Perez Penco, et al.
American Journal of Obstetrics and Gynecology|May 16, 2016
Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancyKarin B Grossman, Roopen Arya, Alberto B Peixoto, et al.
American Journal of Obstetrics and Gynecology|April 17, 2026
In women with chronic hypertension, does fetal growth restriction increase progression to maternal preeclampsia?Laura A Magee, Christos Chatzakis, Argyro Syngelaki, et al.
Obstetric Medicine|December 12, 2017
Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metforminJyoti Balani, Steve Hyer, Argyro Syngelaki, et al.
American Journal of Obstetrics and Gynecology|February 5, 2020
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspringOlga Panagiotopoulou, Argyro Syngelaki, Georgios Georgiopoulos, et al.
Pageof 14